Summary of Significant Accounting Policies (Details Narrative) - USD ($)	3 Months Ended				9 Months Ended		12 Months Ended
	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Cash equivalents
Restricted cash	20,000				20,000
Additional paid-in capital	32,176,064				32,176,064		28,185,599
Impairment losses on long-lived assets
Impairment losses on intangible assets
Impairment losses on goodwill
Reimbursement of actual costs					40,000
Revenue					1,740,855
in-Vivo [Member]
Revenue					500,000
Oncotelic, Inc. [Member]
Due to related parties	$ 500,000				500,000
ATB Agreement [Member] | Japan, China, Brazil, Mexico, Russia and Korea [Member]
Marketing approval received value					1,000,000
ATB Agreement [Member] | Germany, France, Spain, Italy and UK [Member]
Marketing approval received value					$ 2,000,000
JH Darbie & Co., Inc. [Member] | Warrants [Member]
Warrants to purchase common stock	100,000				100,000
Golden Mountain Partners LLC [Member] | Research Service Agreement [Member]
Service fees		$ 900,000	$ 300,000
Autotelic BIO [Member] | ATB Agreement [Member]
Revenue					$ 500,000
Private Placement [Member]
Warrant exercise price per share	$ 0.20				$ 0.20
Private Placement [Member] | JH Darbie & Co., Inc. [Member] | Warrants [Member]
Fair value per share	$ 0.2				$ 0.2
Warrants to purchase common stock	2,915,000				2,915,000
Additional paid-in capital	$ 400,000				$ 400,000
Warrant exercise price per share	$ 0.20				$ 0.20